Berry Genomics Granted CFDA Approval for Birth Defect Test
March 31, 2015 at 05:43 AM EDT
Berry Genomics of Beijing received premarket clearance from the CFDA for the use of an Illumina NextSeq CN500 high-throughput sequencing machine and a Berry-developed non-invasive prenatal test for birth defects. The company's $500 test, which is based on circulating maternal blood serum, offers women with high-risk pregnancies greater safety than the invasive procedure. Berry said its NIPT kits have rates above 99% for both sensitivity and specificity. More details.... Stock Symbol: (NSDQ: ILMN) Share this with colleagues: // //